Picture of Thermogenesis Holdings logo

THMO — Thermogenesis Holdings News Story

0.000.00%
us flag iconLast trade - 00:00
TechnologyHighly SpeculativeMicro Cap

ThermoGenesis Holdings: Falls after Q2 revenue nearly halves

** Shares of cell-based therapy co  THMO.O  fall as much as
20.7% to $3.75 in early trade - lowest in more than 4 months
    ** Co, on Friday, posted Q2 rev of $2.2 mln, nearly half
from a year earlier; attributed decline to low demand for its
proprietary AXP disposable blood processing sets  urn:newsml:reuters.com:*:nPn78SC1Sa
    ** THMO posted loss of $2.6 mln vs profit of $2 mln a year
earlier; co said loss was driven by inventory reserve of ~$3.6
mln for remaining on-hand COVID-19 testing kits from ImmuneCyte
recognized during quarter 
    ** THMO becomes second-worst performer on NASDAQ
    ** YTD, stock up 7.5%
    

 (Reporting by Shreyasee Raj in Bengaluru)
 ((Shreyasee.Raj@thomsonreuters.com;))

Recent news on Thermogenesis Holdings

See all news